WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H596260
CAS#: 133-17-5 (sodium)
Description: o-Iodohippurate sodium is an analogue of p-aminohippuric acid for the determination of effective renal plasma flow. Labelled OIH has a significantly higher clearance than other radiopharmaceutical yet developed and is eminently suitable for renography. It is eliminated mainly by tubular secretion. In patients with normally functioning kidneys, 85% of the OIH may be found in the urine 30 minutes after intravenous injection.
Hodoodo Cat#: H596260
Name: o-Iodohippurate sodium
CAS#: 133-17-5 (sodium)
Chemical Formula: C9H7INNaO3
Exact Mass: 0.00
Molecular Weight: 327.053
Elemental Analysis: C, 33.05; H, 2.16; I, 38.80; N, 4.28; Na, 7.03; O, 14.68
Related CAS #: 5990-94-3 (sodium hydrate) 133-17-5 (sodium)
Synonym: o-Iodohippurate sodium; Hippodin; Sodium iodohippurate NSC 63351; NSC-63351; NSC63351;
IUPAC/Chemical Name: sodium (2-iodobenzoyl)glycinate
InChi Key: XYITYKDGJLHYPW-UHFFFAOYSA-M
InChi Code: InChI=1S/C9H8INO3.Na/c10-7-4-2-1-3-6(7)9(14)11-5-8(12)13;/h1-4H,5H2,(H,11,14)(H,12,13);/q;+1/p-1
SMILES Code: O=C([O-])CNC(C1=CC=CC=C1I)=O.[Na+]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 327.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Mukai T, Fujioka Y, Arano Y, Saji H. [Design of radiolabeled antibody fragments for tumor-selective radioactivity localization--brush border enzyme-sensitive bond to decrease renal accumulation of radioactivity]. Yakugaku Zasshi. 2003 Aug;123(8):647-52. Review. Japanese. PubMed PMID: 12931660.
2: Fine EJ. Interventions in renal scintirenography. Semin Nucl Med. 1999 Apr;29(2):128-45. Review. PubMed PMID: 10321825.
3: Taylor A. Radionuclide renography: a personal approach. Semin Nucl Med. 1999 Apr;29(2):102-27. Review. PubMed PMID: 10321824.
4: el Maghraby TA, van Eck-Smit BL, de Fijter JW, Pauwels EK. Quantitative scintigraphic parameters for the assessment of renal transplant patients. Eur J Radiol. 1998 Oct;28(3):256-69. Review. PubMed PMID: 9881262.
5: Roarke MC, Sandler CM. Provocative imaging. Diuretic renography. Urol Clin North Am. 1998 May;25(2):227-49. Review. PubMed PMID: 9633578.
6: Nagai T. [The measurement of renal plasma flow]. Nihon Rinsho. 1997 Apr;55 Suppl 2:597-600. Review. Japanese. PubMed PMID: 9172599.
7: Piepenburg R, Melchior SW, Steinert H, Hohenfellner R, Hahn K. [Quantitative nuclear medicine kidney diagnosis with kidney tubule traversing radioisotopes]. Urologe A. 1993 Mar;32(2):81-93. Review. German. PubMed PMID: 8475615.
8: Sanger JJ, Kramer EL. Radionuclide quantitation of renal function. Urol Radiol. 1992;14(2):69-78. Review. PubMed PMID: 1509629.
9: Blaufox MD, Dubovsky EV, Hilson AJ, Taylor A Jr, de Zeeuw R. Report of the Working Party Group on Determining the Radionuclide of Choice. Am J Hypertens. 1991 Dec;4(12 Pt 2):747S-748S. Review. PubMed PMID: 1777190.
10: Oei HY. Captopril renography. Early observations and diagnostic criteria. Am J Hypertens. 1991 Dec;4(12 Pt 2):678S-684S. Review. PubMed PMID: 1837990.
11: Abdel-Dayem HM, Turoglu HT. Radionuclide renal studies. Curr Opin Radiol. 1990 Dec;2(6):834-43. Review. PubMed PMID: 2149277.
12: Kowalczyk M. [Possibility of quantitative evaluation of renal function based on the renography alone]. Folia Med Cracov. 1989;30(1-2):45-61. Review. Polish. PubMed PMID: 2701819.
13: Dubovsky EV, Russell CD. Radionuclide evaluation of renal transplants. Semin Nucl Med. 1988 Jul;18(3):181-98. Review. PubMed PMID: 2972068.
14: Velchik MG. Radionuclide imaging of the urinary tract. Urol Clin North Am. 1985 Nov;12(4):603-31. Review. PubMed PMID: 2997967.
15: Mandell VS, Mandell J, Gaisie G. Pediatric urologic radiology. Intervention and endourology. Urol Clin North Am. 1985 Feb;12(1):151-68. Review. PubMed PMID: 2983473.
16: Dubovsky EV, Russell CD. Quantitation of renal function with glomerular and tubular agents. Semin Nucl Med. 1982 Oct;12(4):308-29. Review. PubMed PMID: 6760399.
17: Sherman RA, Byun KJ. Nuclear medicine in acute and chronic renal failure. Semin Nucl Med. 1982 Jul;12(3):265-79. Review. PubMed PMID: 6289457.
18: Chervu LR, Blaufox MD. Renal radiopharmaceuticals--an update. Semin Nucl Med. 1982 Jul;12(3):224-45. Review. PubMed PMID: 6289454.
19: Vetter W, Vetter H, Kuhlmann U, Grüntzig A, Pouliadis G, Meier W, Largiadèr F, Studer A, Siebenschein R, Furrer J, Tenschert W, Siegenthaler W. [Clinical picture, diagnosis and therapy of renovascular hypertension]. Schweiz Med Wochenschr. 1979 Mar 17;109(11):384-94. Review. German. PubMed PMID: 370974.
20: Balogh F, Szomor L. A survey of radioisotope methods used in urological diagnostics. Int Urol Nephrol. 1977;9(3):199-211. Review. PubMed PMID: 344253.
